An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders.
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 11 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 14 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 14 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.